Mix Pyrilutamide powder in Minoxidil solution? 10/5/2023
Mixing Pyrilutamide powder with Minoxidil solution is being considered. The Minoxidil solution contains Minoxidil 5%, Azelaic acid 5%, ABN complex 0.8%, Retinol 0.025%, Caffeine 0.001%, and a delivery vehicle.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity biochemistry bros, is this hair loss solution viable?
The conversation discusses using a combination of finasteride, spironolactone, minoxidil, retinol, azelaic acid, and caffeine for hair loss treatment. The user inquires about the limitations of these drugs and whether tretinoin would be more effective than retinol.
community Pyrilutamide, the molecule's true nature - Research
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
community Has been on minoxidil for 5 years. Microneedling for 4 weeks no results.
The user has used minoxidil for five years and added microneedling for four weeks without seeing results. They are considering a hair transplant but are advised that hair loss will persist without a DHT blocker.
community My personal experience/observations fighting AGA seriously for 5 years
Minoxidil with alcohol and propylene glycol was more effective than non-alcohol versions, and RU58841 worked best in a non-water-based solution. Oral finasteride showed better results than topical, despite side effects; microneedling and tretinoin worsened hair loss, and PRP was only helpful when younger.
community Tfw you’ve been swallowing dut for 6 months and your hair still looks like a mangled birds nest
Hair loss treatments like minoxidil, finasteride, and dutasteride, with mixed results and suggestions for combining treatments or considering hair transplants. Some users experience no improvement or side effects.
Related Research
6 / 6 resultsresearch The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.
research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.